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To assess the value of the central vein sign (CVS) on a clinical 3T scanner to distinguish
between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).
Methods
Eighteen aquaporin-4-antibody-positive patients with NMOSD, 18 patients with relapsing-
remitting MS, and 25 healthy controls underwent 3T MRI. The presence of a central vein in
white matter lesions on susceptibility-weighted imaging, deﬁned as a thin hypointense line or
a small dot, was recorded.
Results
The proportion of lesions with the CVS was higher in MS than NMOSD (80% vs 32%, p <
0.001). A greater proportion of lesions with the CVS predicted the diagnosis of MS, rather than
NMOSD (odds ratio 1.10, 95% conﬁdence interval [CI] 1.04 to 1.16, p = 0.001), suggesting
that each percent unit increase in the proportion of lesions with the CVS in an individual patient
was associated with a 10% increase in the risk of the same patient having MS. If more than 54%
of the lesions on any given scan show the CVS, then the patient can be given a diagnosis of MS
with an accuracy of 94% (95% CIs 81.34, 99.32, p < 0.001, sensitivity/speciﬁcity 90%/100%).
Conclusion
The clinical value of the CVS in the context of the diﬀerential diagnosis between MS and
NMOSD, previously suggested using 7T scanners, is now extended to clinical 3T scanners,
thereby making a step towards the use of CVS in clinical practice.
Classification of evidence
This study provides Class III evidence that the CVS on 3T MRI accurately distinguishes
patients with MS from those with seropositive NMOSD.
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MRI has an important role in the diagnosis of neuromyelitis
optica spectrum disorder (NMOSD) and multiple sclerosis
(MS).1 The diﬀerentiation between the 2 diseases is often chal-
lenging, since clinical manifestations may overlap, and up to 70%
of patients with NMOSD have brain lesions on MRI.2 An ac-
curate diﬀerentiation between these 2 diseases is crucial, because
some MS therapies cause disease worsening in NMOSD.3–5
Advanced MRI techniques may provide biomarkers that help
the diﬀerential diagnosis.6 Recent studies at 7T have shown
that the presence of the central vein sign (CVS) within white
matter lesions is a hallmark of MS and diﬀerentiates MS from
NMOSD.7–9 However, 7T scanners are not routinely avail-
able in the clinical setting. Further investigations that evaluate
the clinical value of the CVS for the diﬀerential diagnosis of
MS are needed.10,11
The aim of this study was to investigate the predictive value of
the CVS when using a clinical 3T scanner for diﬀerentiating
seropositive NMOSD from MS.
Methods
Our primary question was whether the CVS on a clinical 3T
scanner distinguishes between seropositive NMOSD andMS.
Study participants
We prospectively recruited patients from the NMO Clinical
Service at the Walton Centre, Liverpool, and the National
Hospital for Neurology and Neurosurgery, London, UK. The
inclusion criteria were (1) diagnosis of AQP4-antibody-pos-
itive NMOSD according to 2015 Wingerchuk criteria1 or
diagnosis of relapsing-remitting MS (RRMS),12,13 which has
a relapsing course as NMOSD; (2) absence of relapses within
6 months before the MRI scan; and (3) no major contra-
indications to MRI. We did not consider the presence of
comorbidities as an exclusion criterion. Neurologic disability
was assessed with the Expanded Disability Status Scale
(EDSS)14 on the date of the MRI scan. Healthy controls were
recruited to match the age and sex of patients.
Standard protocol approvals, registrations,
and patient consents
Written informed consent was obtained from all participants;
this study was approved by the NRES Committee London
Bloomsbury.
MRI data acquisition
We acquired MRI scans using a 3T Philips Achieva MRI
system with dual-transmit technology (Philips Healthcare,
Best, the Netherlands) and 32-channel head coil. The pro-
tocol included a dual-echo proton density/T2-weighted se-
quence and susceptibility-weighted imaging (SWI)
(precontrast), using a 3D fast ﬁeld echo sequence with shifted
echo and no phase multiplication (acquisition measures:
repetition time 16 ms, echo time 23 ms, ﬂip angle 10°, ﬁeld of
view 240 × 180 mm2, voxel size 1 × 1 × 1 mm3 [reconstructed
to 0.5 × 0.5 × 0.5 mm3], number of averages 1, axial contig-
uous slices = 270, scanning time 7 minutes).
Image processing and analysis
A senior neuroradiologist (F.B.) and a trained rater (R.C.)
identiﬁed the white matter lesions on the proton density/
T2-weighted MRI, which were then contoured using
a semiautomated edge ﬁnding tool (JIM v.6.0, Xinapse
systems; xinapse.com). Only lesions with a diameter
≥3 mm in at least one plane were contoured; care was taken
to exclude punctate round white matter lesions that may
have represented age-related vascular abnormalities.
Lesions were classiﬁed as infratentorial, periventricular
(with one edge in contact with a ventricle), deep white
matter, and juxtacortical (with one edge in contact with the
cortex). The T2-weighted images were aﬃne coregistered
to the SWI using a symmetric and inverse-consistent
approach.15,16 Afterwards, the T2 lesion masks were
resampled to the corresponding SWI using the trans-
formation measures obtained from the previous step. All
registrations were done using the NiftyReg software
package (niftyreg.sf.net) (ﬁgure e-1, links.lww.com/WNL/
A310).
The identiﬁcation of the CVS on SWI was based on the
consensus between 2 readers (R.C., T.Y.). Depending on
the slice angle, the CVS was either depicted as a centrally
located, thin, hypointense line or a small dot, running
partially or entirely through the lesion, visualized in at least
2 perpendicular planes. Veins that did not run through the
center of the lesion, but were located somewhere in its
periphery in all planes, were not counted. The inclusion
and exclusion criteria for the radiologic deﬁnition of the
CVS, as recently recommended by Sati and colleagues,11
were followed. All readers worked independently and were
blinded to clinical data.
To ensure that the scoring of the CVS was not inﬂuenced
by the overall appearance of the scan, we performed an
additional, fully blinded analysis using 165 lesions ran-
domly selected from 4 patients with MS and 4 patients with
NMOSD. These lesions were individually isolated and the
SWI were then cropped in 3D around each individual
Glossary
CI = conﬁdence interval; CVS = central vein sign; EDSS = Expanded Disability Status Scale; MS = multiple sclerosis;
NMOSD = neuromyelitis optica spectrum disorder; OR = odds ratio; RRMS = relapsing-remitting multiple sclerosis; SWI =
susceptibility-weighted imaging.
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lesion, so that all the other white matter lesions, and the
remainder of the brain, were not visible (ﬁgure e-2, links.
lww.com/WNL/A310). The identiﬁcation of the CVS was
done as explained above.
Statistical analysis
MS, NMOSD, and healthy control groups were compared in
terms of age, sex, disease duration, EDSS, and lesion charac-
teristics using χ2 test, linear regression, or Mann-Whitney U
tests depending on the nature of the variable. The analysis for
this study was divided into the following 2 parts.
Prediction of MS vs NMOSD based on the
proportion of lesions with the CVS
Logistic regression models were ﬁtted, where the type of
disease was the dependent variable and the proportion of
lesions with the CVS was the independent variable.
The median number of T2 white matter lesions was cal-
culated considering all patients together (MS and
NMOSD) and then used to divide patients in 2 groups: (1)
patients with a small amount of lesions (below the median
number of lesions); (2) patients with a large amount of
lesions (above or at the median value). In each group, the
proportion of lesions showing the CVS was calculated to
identify the best cutoﬀ (i.e., the value associated with the
highest accuracy) that predicted the outcome (e.g., a di-
agnosis of MS rather than NMOSD) using receiver oper-
ating characteristic analysis. The same analysis was re-run
using a cutoﬀ of 40%, which was previously reported to be
able to distinguish MS from non-MS disease.7
For all these models, age, sex, disease duration, total number
of lesions, and (individual) mean lesion volumes were ex-
plored as covariates. EDSS score was also used as a covariate.
To further investigate the clinical feasibility of the CVS, we
tested “pick 6” and “pick 3” algorithms,17,18 which were
proposed as less time-consuming methods of counting
lesions with the CVS to predict the diagnosis of MS. For
pick 6, we used 6 randomly selected lesions on SWI to
allocate the scans into the disease category (presence/
absence of inﬂammation). For pick 3, the CVS was evalu-
ated in 3 lesions in the deep white matter randomly selected
in each patient.
Predictors of the presence of the CVS in white
matter lesions
Considering only patients with lesions, we ﬁrst ﬁtted univar-
iate univariable generalized linear models for grouped binary
data (clustered at the individual level). For these models, the
probability of a lesion with the CVS was considered as the
dependent variable, and the following variables were consid-
ered individually as the independent predictors: type of dis-
ease, age, mean lesion volume, disease duration. Second,
univariate multivariable models were ﬁtted, where the prob-
ability of a lesion with the CVS was again considered as the
dependent variable, and all the covariates were included to-
gether as independent variables.
For both part I and part II, odds ratio (OR) and its corre-
sponding 95% conﬁdence interval (CI) are presented.
The Cohen kappa coeﬃcient measured the agreement in the
identiﬁcation of the CVS between the fully blinded scoring
(using the SWI cropped around each lesion) and the scoring
of the CVS when using the whole images.
All tests were performed using STATA 14.2. Statistical sig-
niﬁcance was considered when p values were <0.05.
This work provides Class III evidence because of the case–
control design and the risk of spectrum bias.
Results
Patients with NMOSD were older than patients with MS and
healthy controls, and had higher disability than patients with
MS; disease duration did not diﬀer between the 2 patient
Table 1 Clinical and demographic characteristics of patients with neuromyelitis optica spectrum disorder (NMOSD) and
relapsing-remitting multiple sclerosis (RRMS) and healthy controls
NMOSD RRMS Healthy controls p Value
No. of participants 18 18 25 —
Sex, male/female 4/14 4/14 7/18 0.868a
Mean age, y (±SD) 52.5 (±2.8) 41.8 (±2.8) 37.1 (±2.4) <0.001,b 0.009c
Mean disease duration, y (±SD) 8.6 (± 7.3) 9 (± 6.4) NA 0.870d
Median EDSS (range) 5 (2–6.5) 2.5 (1–7.5) NA 0.011e
a Obtained using the χ2 test, to compare the 3 subject groups.
b Obtained using a linear regression, to compare the 3 subject groups.
c Obtained using a linear regression, to compare RRMS to NMOSD.
d Obtained using a linear regression, to compare RRMS to NMOSD.
e Obtained using Mann-Whitney U test, to compare RRMS to NMOSD.
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groups (table 1). A total of 18/18 (100%) patients with MS
and 12/18 (66%) patients with NMOSD met the revised
McDonald MRI criteria for dissemination in space.12 A total
of 3/18 (17%) patients with NMOSD had cardiovascular risk
factors (diabetes mellitus or hypercholesterolemia), and 14/
18 (78%) patients with NMOSD showed a lesion longer than
3 vertebral segments on MRI.
Lesions with the CVS: Count and location
A total of 783 white matter lesions were seen in 18 out of 18
(100%) patients with MS, 186 lesions were detected in 16/18
(88%) patients with NMOSD, and 11 lesions were seen in 4/
25 (16%) healthy controls. The median number of white
matter lesions in all patients together (MS and NMOSD) was
11. Table 2 shows the number and characteristics of lesions in
the 3 groups of participants.
A typical example of a lesion with the CVS is shown in ﬁgure
1. The proportion of lesions with the CVS was higher in MS
(80%) than NMOSD (32%) (table 2, ﬁgure 2). No lesions in
healthy controls showed the CVS.
There was a very good agreement in the identiﬁcation of the
CVS between the fully blinded procedure and the original
scoring method (Cohen kappa coeﬃcient 0.95, standard error
0.0169, 95% CI 0.9183–0.9847).
In NMOSD, the highest proportion of lesions with the CVS,
out of the total number of lesions with the CVS, was seen in
the periventricular location (53%), while in MS the highest
proportion of lesions with the CVS was detected in the deep
white matter (56%). The proportion of lesions with the CVS
in the deep white matter, out of the total number of lesions in
the same location, was higher in MS than NMOSD (87% vs
16%, respectively; p < 0.001); no diﬀerences in the proportion
of lesions with the CVS in the periventricular region, out of
the total number of lesions in the same location, were ob-
served between the 2 conditions (table e-1, links.lww.com/
WNL/A311).
Prediction of MS vs NMOSD based on the
proportion of lesions with the CVS
A greater proportion of lesions with CVS was predictive of
MS (instead of NMOSD) (OR 1.10, 95% CI 1.04–1.16, p =
0.001): per each percent unit increase in the proportion of
lesions with CVS in a given patient, this patient had a 10%
higher risk of having MS instead of NMOSD. When this
model was adjusted for age, sex, disease duration, and total
number of lesions, similar results were obtained.
The best cutoﬀ value in respect to the proportion of lesions with
the CVS that predicted the diagnosis of MS, when all patients
were included together, was 54% (table 3). Figure e-3 (links.lww.
com/WNL/A310) shows the ﬂow diagram of patients.19 This
cutoﬀ indicates that if more than 54% of the white matter lesions
seen on any given scan show the CVS, then the patient can be
given a diagnosis of MS. Similarly, when only patients with ≥11
lesions were considered, the best cutoﬀ to diagnose MS
remained 54%. When only patients with <11 lesions were con-
sidered, the proportion of lesions with the CVS that best pre-
dicted the diagnosis of MS was 80%.
When 40% was used as a cutoﬀ, sensitivity, speciﬁcity, and
accuracy of the cutoﬀ changed when all patients and patients
Table 2 Lesion numbers and characteristics inmultiple sclerosis (MS), neuromyelitis optica spectrumdisorder (NMOSD),
and healthy controls
NMOSD MS Healthy controls
Participants with white matter lesions, n (%) 16/18 (88) 18/18 (100) 4/25 (16)
Total number of lesions 186 783 11
Number of lesions per participant, mean (±SD) 10.3 (±16.8) 43.5 (±27.8)a 0.44 (±1.3)
Number of lesions per participant, median (range) 5 (0–70) 36.5 (5–86) 0 (0–5)
Lesions with CVS/total number of lesions, n (%) 59/186 (32) 625/783 (80)a 0
Range of % of lesions with CVS 0%–100%b 53.85%–100% 0
Number of lesions with CVS per participant, mean (±SD) 3.3 (±4.4) 34.7 (±22.3) 0
Number of lesions with CVS per participant, median (range) 2 (0–13) 31.5 (4–67) 0
Lesion volume, mm³, mean (±SD) 1,991 (±2,648.3) 8,861.8 (±7,942.7)a 269.2 (±183.4)
CVS lesion volume, mm³, mean (±SD) 1,437.8 (±1,771.9) 8,325.4 (±7,704.2) 0
Non-CVS lesion volume, mm³, mean (±SD) 738.4 (±1,223.8) 596.5 (±414.3) 269.2 (±183.4)
Abbreviations: CVS = central vein sign; CVS lesion volume = volumeof lesionswith central vein sign; non-CVS lesion volume = volumeof lesionswithout central
vein sign.
a p < 0.001, obtained using linear regression, to compare relapsing-remitting MS to NMOSD.
b One patient had only one lesion and this lesion showed the CVS (resulting in 100%).
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with <11 lesions were considered, but remained stable when
only patients with ≥11 white matter lesions were included
(table 3).
Results of the pick 6 and pick 3 algorithms showed that pick 6
was sensitive (100% [95% CI 81.47%–100.00%]) but not
speciﬁc (88.89% [95% CI 65.29%–98.62%]), and pick 3 was
speciﬁc (100.00% [95% CI 81.47%–100.00%]) but not sen-
sitive (50.00% [95% CI 26.02%–73.98%]) for the diagnosis
of MS.
Predictors of the presence of the CVS in white
matter lesions
When using univariable models, only the variable “disease
type” was associated with the probability of a lesion showing
the CVS. In other words, the risk of ﬁnding the CVS in a le-
sion was greater if that lesion belonged to a patient with MS
than NMOSD (OR 8.51 [95% CI 4.3–16.7], p < 0.001).
Age, sex, mean lesion volume, or disease duration were
not associated with the probability of a lesion showing
the CVS. The multivariable models conﬁrmed that only the
disease type was associated with the presence of the CVS.
Discussion
We have validated the use of the CVS to support the dif-
ferential diagnosis between MS and NMOSD by using
a clinical 3T scanner, thereby extending early results
obtained at 7T.8,9 We found that the presence of ≥54% of
white matter lesions with the CVS predicted a diagnosis of
MS with a high accuracy, high sensitivity, and high speci-
ﬁcity. This means that 90% of patients with MS were cor-
rectly identiﬁed as having MS and 100% of patients with
NMOSD were correctly identiﬁed as not having MS. The
40% rule (>40% of white matter lesions with the CVS),
which was proposed previously when using T2*-weighted
imaging at 7T in all phenotypes of MS to distinguish it from
non-MS,7 is not the best cutoﬀ when studying patients with
RRMS and NMOSD using a clinical 3T scanner and in-
cluding all lesions. Only when patients with a large number
Figure 1 Example of lesions with the central vein sign (CVS) in multiple sclerosis (MS) and without CVS in neuromyelitis
optica spectrum disorder (NMOSD)
Axial proton density (A, C) and corresponding
susceptibility-weighted imaging (B, D) of peri-
ventricular lesions inMS (A, B) andNMOSD (C, D).
The dark vein is located centrally in the majority
of the lesion in MS (white arrow). On the other
hand, a central vein is absent in most of the
lesions of a patient with NMOSD (black arrows).
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of lesions were included, the accuracy of the 40% cutoﬀ is
high.
Interestingly, we found that the 54% cutoﬀ worked equally
well when all patients were considered together regardless of
their total number of lesions, and when patients with at least
11 lesions (e.g., median number of lesions) were included.
When patients with fewer than 11 lesions were analyzed,
a much higher cutoﬀ of 80% was identiﬁed, and this was
associated with lower accuracy, lower sensitivity, and lower
speciﬁcity, probably because patients with NMOSD tend to
show a low number of white matter lesions.
Overall, the use of a cutoﬀ has been criticized by the fact that
counting all lesions in clinical practice may be unachievable,
especially in patients with high lesion load.11 In addition,
varying cutoﬀ values depending on lesion burden may be
diﬃcult to achieve with clinical scans, and applying the rec-
ommended inclusion/exclusion criteria11 requires advanced
radiologic expertise.
We used pick 6 and pick 3 algorithms for the diagnosis of
MS,17,18 but we found that they were not superior to the 54%
cutoﬀ. Although the visual detection of the CVS can be
inﬂuenced by the overall appearance of the MRI, the fully
blinded analysis on a subgroup of randomly chosen lesions
strongly suggests that this did not occur. Automatic
algorithms for lesion segmentation20 are being optimized and
validated, and they may facilitate the translation of the CVS to
clinical practice, as lesion identiﬁcation can be done auto-
matically. An important step towards the use of CVS in
clinical practice is to validate this cutoﬀ value using large,
multicenter studies, recruiting patients at disease onset and
using standardized MRI protocols.
An interesting observation is that there is a higher percentage
of the CVS in MS (80%) than NMOSD (32%) lesions. This
ﬁnding highlights the diﬀerent pathophysiologic mechanisms
underlying lesion development in these 2 disorders. Patho-
logic studies21 and ultrahigh-ﬁeld MRI studies22 have sug-
gested that MS lesions grow outward from a central vein. The
perivascular space is thought to be a privileged site for lym-
phomonocytic inﬁltrates, which can trigger an inﬂammation
reaction and demyelination and lead to the centrifugal ex-
pansion of lesions around the veins.21 However, in long-
standing MS, the widespread tissue damage may lead to
decreased levels of oxygen extraction, which, in turn, reduces
the visibility of the veins on MRI at ultrahigh ﬁeld.23,24 One
possible explanation is that younger lesions show the CVS,
while more chronic lesions do not. Further imaging studies
will test this hypothesis.
On the other hand, pathologic studies have demonstrated that
in NMOSD the massive astrocytic damage is of primary
Figure 2 Proportion of lesions with the central vein sign (CVS) in patients with multiple sclerosis (MS) and AQP4-antibody-
positive neuromyelitis optica spectrum disorder (NMOSD)
The scatterplot shows the proportion of lesions with CVS
(out of the total number of lesions) in MS and NMOSD.
Patients with NMOSD without brain lesions (n = 2) are not
displayed. The dotted line indicates the 54% cutoff that
distinguished between MS and NMOSD using receiver op-
erating characteristic analysis.
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importance in the development of lesions and that myelin
damage may be a secondary phenomenon due to the un-
derlying astrocyte pathology.25 Therefore, the CVS found in
a small number of NMOSD lesions may indicate that de-
myelination follows the primary astrocytic injury, while the
absence of the CVS may indicate that the central vein has
become occluded and therefore not visible on MRI.
In line with previous studies,7,18 when lesions were classiﬁed
according to their location, MS lesions demonstrated the CVS
more frequently in deep white mater than NMOSD lesions,
which were more likely to show the CVS in the periventricular
location. This is also in agreement with the previous report of
reduced periventricular venous visibility inMS thanNMOSD,
as a consequence of more extensive brain parenchymal gliosis
in MS.26
From a clinical perspective, we hypothesize that the practical
utility of the CVS is that its absence at the onset of optic
neuritis or transverse myelitis would support a diagnosis of
seropositive NMOSD, but this needs to be tested and vali-
dated in studies including patients with seropositive and se-
ronegative NMOSD and patients at an early stage of their
disease, when the number of lesions may be low, therefore
reducing the discriminatory value of the CVS.
From a technical point of view, SWI is a technique used in
clinical practice to aid the diagnosis of cerebral vascular dis-
eases.27 We used a high-resolution sequence with high sen-
sitivity to susceptibility eﬀects, which can bemade available on
3T clinical scanners and is relatively quick to acquire, so that
its translation to clinical practice may be achievable.28,29
Contrast-enhanced susceptibility images can further enhance
the visualization of small parenchymal veins,30 thus increasing
the sensitivity of the technique in detecting the CVS.
However, the eﬀect of gadolinium injection on the cutoﬀ for
the diﬀerential diagnosis between MS and NMOSD has to be
evaluated.
This study is not without limitations. First, we only recruited
patients with seropositive NMOSD. Also, in line with the
known disease demographics, patients with NMOSD were
older than patients withMS, and it is expected that age-related
vascular lesions increase the lesion load in older patients.
Moreover, all the statistical models were corrected for age and
we did not ﬁnd any association between age and risk of a le-
sion having the CVS.
The key questions that need to be addressed in future studies
are whether the presence of the CVS at 3T early in clinically
isolated syndrome is associated with a higher risk of de-
veloping MS, so that this sign can be included in the revised
criteria for the diagnosis of MS, and what is the longitudinal
evolution of the lesions with CVS. Moreover, no in vivo
reports are available to assess the value of the CVS in MS
spinal cord lesions and in pediatric MS brains.
The identiﬁcation of the CVS on SWI at 3T MRI is of high
clinical relevance as it may facilitate an accurate diﬀerentiation
between MS and NMOSD. It also provides insights into the
pathophysiologic processes underlying these 2 diﬀerent
diseases.
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When all patients were included regardless of the
number of white matter lesions
54 90 (68–99) 100 (79–100) 94 (81–99) 0.92 (0.80–1)
When patients with small number of white matter
lesions were included (<11)
80 50 (1–99) 93 (68–100) 88 (64–99) 0.93 (0.80–1)
When patients with large number of white matter
lesions were included (≥11)
54 94 (71–100) 100 (16–100) 94 (74–100) 0.83 (0.50–1)
When all patients were included regardless of the
number of white matter lesions (cutoff
predetermined)
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When patients with small number of white matter
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Can the central vein sign (CVS) on a clinical 3T MRI scanner
distinguish multiple sclerosis (MS) from seropositive neuro-
myelitis optica spectrum disorder (NMOSD)?
Summary answer
CVS on a clinical 3T MRI scanner can distinguish MS from
seropositive NMOSD.
What is known and what this paper adds
CVS detection with a 7-TMRI scanner can distinguish MS from
NMOSD, but such ultrahigh-ﬁeld scanners are not clinically
available. This study provides Class III evidence that clinical 3T
MRI scanners can be used instead.
Participants and setting
This study examined 18 patients with aquaporin-4 antibody-
positive NMOSD and 18 patients with relapsing-remitting
MS from 2 centers in the UK (the NMO Clinical Service at
the Walton Centre, Liverpool, and the National Hospital for
Neurology and Neurosurgery, London). Twenty-ﬁve healthy
controls matched in age and sex with the patients were also
recruited.
Design, size, and duration
Diagnosis of NMOSD orMS was made according to standardized
criteria. Participants underwent a 3TMRI scan and dual-echo PD/
T2-weighted sequence and susceptibility-weighted imaging (SWI)
were acquired. After identifying white matter lesions on the PD/
T2-weighted sequences, the CVS was depicted on SWI as a cen-
trally located line or a small dot, running partially or entirely
through the lesion, visualized in at least 2 perpendicular planes.
CVS identiﬁcations was performed by readers blinded to partic-
ipants’ diagnoses.
Main results and the role of chance
There were 783 white matter lesions in 18 (100%) patients with
MS, 186 white matter lesions in 16 (88%) patients with NMOSD,
and 11 white matter lesions in 4 (16%) healthy controls. The CVS
was detected in 80% of lesions in patients with MS, 32% of lesions
in patients with NMOSD, and no lesions in healthy controls. A
greater proportion of CVS-positive lesions diﬀerentiatedMS from
NMOSD (OR: 1.10; 95%CI, 1.04–1.16; p= 0.001). A 54% cut-oﬀ
proportion of lesions with CVS distinguished MS from NMOSD
with 94% accuracy (95%CI, 81%–99%; p< 0.001), 90% sensitivity
(95% CI, 68%–99%), and 100% speciﬁcity (95% CI, 79%–100%).
Bias, confounding, and other reasons
for caution
Patients with NMOSDwere older than those withMS and older
patients generally have more vascular lesions.
Generalizability to other populations
Only patients with an established diagnosis of seropositive
NMOSD were recruited. This may limit generalizability to
patients with seronegative NMOSD and patients at early stages
of disease.
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